Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310553624> ?p ?o ?g. }
- W4310553624 endingPage "542" @default.
- W4310553624 startingPage "534" @default.
- W4310553624 abstract "In solid organ transplant recipients, skin cancer risk associated with posttransplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used posttransplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF (tumor necrosis factor)-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors such as natalizumab, targeted B-cell, and T-cell inhibitors including CD20 (cluster of differentiate 20), CD52, and BTK (Bruton's tyrosine kinase) inhibitors, and JAK (Janus kinase) inhibitors is reviewed. Based on the available data, we recommend regular skin cancer screening for select nontransplant patients receiving immunosuppressive regimens that are shown to raise the risk of NMSC or melanoma. We also offer suggestions for conscientious use of these therapies in high-risk patients. Finally, a comprehensive summary of the relative risk associated with each immunosuppressant class and associated recommendations is presented. In solid organ transplant recipients, skin cancer risk associated with posttransplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used posttransplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF (tumor necrosis factor)-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors such as natalizumab, targeted B-cell, and T-cell inhibitors including CD20 (cluster of differentiate 20), CD52, and BTK (Bruton's tyrosine kinase) inhibitors, and JAK (Janus kinase) inhibitors is reviewed. Based on the available data, we recommend regular skin cancer screening for select nontransplant patients receiving immunosuppressive regimens that are shown to raise the risk of NMSC or melanoma. We also offer suggestions for conscientious use of these therapies in high-risk patients. Finally, a comprehensive summary of the relative risk associated with each immunosuppressant class and associated recommendations is presented. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroidsJournal of the American Academy of DermatologyVol. 88Issue 3PreviewImmunosuppression is a well-documented risk factor for skin cancer, as exemplified by the 65- to 250-fold higher squamous cell carcinoma risk, 10-fold higher basal cell carcinoma risk, and 0 to 8-fold higher melanoma risk in solid organ transplant recipients (SOTRs) receiving potent, prolonged courses of immunosuppressive therapies. Numerous immune system components have been shown to either suppress or promote tumor growth, and immunosuppressive drugs may have additional effects on proliferative pathways independent of the immune system. Full-Text PDF CME examinationJournal of the American Academy of DermatologyVol. 88Issue 3Preview Full-Text PDF" @default.
- W4310553624 created "2022-12-12" @default.
- W4310553624 creator A5001686012 @default.
- W4310553624 creator A5004065744 @default.
- W4310553624 creator A5034956267 @default.
- W4310553624 creator A5056072331 @default.
- W4310553624 creator A5070117894 @default.
- W4310553624 date "2023-03-01" @default.
- W4310553624 modified "2023-10-02" @default.
- W4310553624 title "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors" @default.
- W4310553624 cites W1892676932 @default.
- W4310553624 cites W1968559028 @default.
- W4310553624 cites W2005490856 @default.
- W4310553624 cites W2067296586 @default.
- W4310553624 cites W2080450248 @default.
- W4310553624 cites W2083136482 @default.
- W4310553624 cites W2098062273 @default.
- W4310553624 cites W2118447813 @default.
- W4310553624 cites W2159197023 @default.
- W4310553624 cites W2166305732 @default.
- W4310553624 cites W2169778736 @default.
- W4310553624 cites W2297295070 @default.
- W4310553624 cites W2357015347 @default.
- W4310553624 cites W2431658434 @default.
- W4310553624 cites W2468901930 @default.
- W4310553624 cites W2559106304 @default.
- W4310553624 cites W2583474867 @default.
- W4310553624 cites W2650090085 @default.
- W4310553624 cites W2777952438 @default.
- W4310553624 cites W2903783989 @default.
- W4310553624 cites W2922089356 @default.
- W4310553624 cites W2948598785 @default.
- W4310553624 cites W2995287555 @default.
- W4310553624 cites W2997321472 @default.
- W4310553624 cites W3000133404 @default.
- W4310553624 cites W3005664296 @default.
- W4310553624 cites W3028017255 @default.
- W4310553624 cites W3107555666 @default.
- W4310553624 cites W3120916484 @default.
- W4310553624 cites W3157451319 @default.
- W4310553624 cites W3179893073 @default.
- W4310553624 cites W3195950510 @default.
- W4310553624 cites W3198682796 @default.
- W4310553624 cites W3205476551 @default.
- W4310553624 cites W4200112816 @default.
- W4310553624 cites W4210529991 @default.
- W4310553624 cites W4293802238 @default.
- W4310553624 doi "https://doi.org/10.1016/j.jaad.2022.11.043" @default.
- W4310553624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36460256" @default.
- W4310553624 hasPublicationYear "2023" @default.
- W4310553624 type Work @default.
- W4310553624 citedByCount "6" @default.
- W4310553624 countsByYear W43105536242023 @default.
- W4310553624 crossrefType "journal-article" @default.
- W4310553624 hasAuthorship W4310553624A5001686012 @default.
- W4310553624 hasAuthorship W4310553624A5004065744 @default.
- W4310553624 hasAuthorship W4310553624A5034956267 @default.
- W4310553624 hasAuthorship W4310553624A5056072331 @default.
- W4310553624 hasAuthorship W4310553624A5070117894 @default.
- W4310553624 hasConcept C121608353 @default.
- W4310553624 hasConcept C126322002 @default.
- W4310553624 hasConcept C143998085 @default.
- W4310553624 hasConcept C16005928 @default.
- W4310553624 hasConcept C17991360 @default.
- W4310553624 hasConcept C203014093 @default.
- W4310553624 hasConcept C2777138892 @default.
- W4310553624 hasConcept C2777575956 @default.
- W4310553624 hasConcept C2777789703 @default.
- W4310553624 hasConcept C2778886723 @default.
- W4310553624 hasConcept C2780252810 @default.
- W4310553624 hasConcept C2780564577 @default.
- W4310553624 hasConcept C2780969348 @default.
- W4310553624 hasConcept C71924100 @default.
- W4310553624 hasConceptScore W4310553624C121608353 @default.
- W4310553624 hasConceptScore W4310553624C126322002 @default.
- W4310553624 hasConceptScore W4310553624C143998085 @default.
- W4310553624 hasConceptScore W4310553624C16005928 @default.
- W4310553624 hasConceptScore W4310553624C17991360 @default.
- W4310553624 hasConceptScore W4310553624C203014093 @default.
- W4310553624 hasConceptScore W4310553624C2777138892 @default.
- W4310553624 hasConceptScore W4310553624C2777575956 @default.
- W4310553624 hasConceptScore W4310553624C2777789703 @default.
- W4310553624 hasConceptScore W4310553624C2778886723 @default.
- W4310553624 hasConceptScore W4310553624C2780252810 @default.
- W4310553624 hasConceptScore W4310553624C2780564577 @default.
- W4310553624 hasConceptScore W4310553624C2780969348 @default.
- W4310553624 hasConceptScore W4310553624C71924100 @default.
- W4310553624 hasIssue "3" @default.
- W4310553624 hasLocation W43105536241 @default.
- W4310553624 hasLocation W43105536242 @default.
- W4310553624 hasOpenAccess W4310553624 @default.
- W4310553624 hasPrimaryLocation W43105536241 @default.
- W4310553624 hasRelatedWork W1989894409 @default.
- W4310553624 hasRelatedWork W2036344824 @default.
- W4310553624 hasRelatedWork W2169053128 @default.
- W4310553624 hasRelatedWork W2398457950 @default.
- W4310553624 hasRelatedWork W2404038155 @default.
- W4310553624 hasRelatedWork W2409911676 @default.